Valneva Reports Positive Phase 2 Results for Shigella Vaccine S4V2 in Infants and Adults

20 November 2026 | Friday | Interaction

The investigational vaccine demonstrated immune responses against four Shigella serotypes in infants and protection against Shigella sonnei disease in adults, supporting further clinical development.
Editor: BioPharma Boardroom

Editor: BioPharma Boardroom

Shigellosis remains a major cause of diarrhoeal illness in young children, particularly in low- and middle-income countries, with no licensed vaccine currently available. Valneva's S4V2 candidate has shown encouraging safety, immunogenicity and efficacy findings across two Phase 2 studies, although further work is needed to optimise dosing and protection. BioPharma Boardroom speaks with Thomas Lingelbach, CEO Valneva about the clinical findings, challenges in Shigella vaccine development and the next steps towards larger trials and potential global access.

Q. Valneva has reported positive results from two Phase 2 studies of its Shigella vaccine candidate, S4V2. What do these findings mean for the program, and how do they strengthen the case for advancing the vaccine into later-stage development?

The results from both Phase 2 studies represent an important milestone for the S4V2 program. 

Data from the infant immunogenicity and safety trial demonstrated a favorable safety and tolerability profile, along with statistically significant increases in anti-LPS IgG antibody levels against all four targeted serotypes at both dose levels evaluated.

The second trial, conducted in healthy adults using a controlled human infection model (CHIM), assessed safety, immunogenicity, and efficacy. The trial met its pre-specified primary endpoint, demonstrating statistically significant protection against Shigella sonnei-associated disease compared with placebo. It also confirmed a favorable safety profile and generated encouraging immunogenicity results.

Valneva is further analyzing the complete dataset including potential optimization approaches that could be assessed in future clinical studies to determine the most appropriate path forward. 

Q. The infant study in Kenya showed immune responses against all four targeted Shigella serotypes, with antibody levels remaining above baseline six months after vaccination. How significant are these findings, particularly for protecting young children in regions where shigellosis is a major health concern?

These findings are particularly encouraging given that children under five years of age bear the greatest burden of shigellosis globally. Demonstrating immune responses against all four vaccine-targeted serotypes is important because protection against multiple circulating strains will likely be essential for achieving meaningful public health impact. 

We were also encouraged to observe that antibody levels remained above baseline six months after vaccination, indicating persistence of the immune response. While additional studies may be needed to further enhance antibody titres and durability before advancing to efficacy evaluation, these data, support the potential of S4V2 to contribute to the prevention of shigellosis in the populations most affected by the disease, particularly in low- and middle-income countries where it continues to cause significant morbidity and mortality.

Q. The controlled human infection model study in the United States met its primary endpoint, demonstrating protection against Shigella sonnei-associated disease. What have you learned from this trial, and how could the findings help predict vaccine performance in populations at higher risk of infection?

The CHIM study provides one of the most direct assessments of vaccine efficacy available before conducting large field efficacy trials. In this study, S4V2 met its primary endpoint, demonstrating a statistically significant reduction in shigellosis caused by Shigella sonnei compared with placebo. 

Importantly, the study helped us to better understand which level of vaccine-induced immune responses may translate into disease protection. While challenge studies cannot fully replicate the epidemiological and environmental conditions encountered in endemic regions, they can provide valuable insights into protective mechanisms and help inform the design of future efficacy studies. Combined with the infant immunogenicity data, the CHIM results provide additional confidence that the immune responses induced by S4V2 have the potential to be clinically meaningful. Further analyses are ongoing and will help refine our understanding of the vaccine's performance. 

Q. The infant study also highlighted the need to optimize vaccine dosing and scheduling. What are the main questions you still need to address, and how will these influence the design of future clinical trials?

The infant study achieved its key objectives regarding safety and immunogenicity, but it also highlighted opportunities to further optimize the vaccine regimen. As we continue to analyze the complete dataset, we are evaluating factors such as dose selection, vaccination schedule, and how best to maximize the breadth, magnitude, and durability of the immune response across all four targeted serotypes. 

The answers to these questions will help determine the most appropriate vaccination strategy for future studies and ultimately for the populations we aim to protect. Our next clinical development steps will be informed by a comprehensive assessment of both the infant and CHIM datasets to ensure that subsequent trials are designed to generate the strongest possible evidence package. 

Q. Despite the substantial global burden of shigellosis, there is currently no licensed vaccine. What have been the biggest challenges in developing an effective Shigella vaccine, and how could S4V2 help address the needs of children in low- and middle-income countries?

Shigella vaccine development has historically been challenging for several reasons. The disease is caused by multiple serotypes, which means a successful vaccine needs to provide broad coverage. In addition, the highest-risk population is very young children, who can respond differently to vaccination than adults. Establishing clear correlates of protection has also been a challenge for the field. 

S4V2 was designed as a tetravalent vaccine candidate targeting four major Shigella serotypes. The Phase 2 data showing immune responses against all four targeted serotypes in infants and efficacy against S. sonnei in the CHIM study are encouraging steps toward addressing these longstanding challenges. If successfully developed, S4V2 could help fill a significant unmet medical need, particularly in low- and middle-income countries where shigellosis remains a leading cause of diarrheal disease and where growing antimicrobial resistance further underscores the need for preventive solutions. 

Q. With the complete Phase 2 datasets under review and FDA Fast Track designation already granted, what are Valneva's next development priorities for S4V2, and what role could partnerships with global health organizations play in supporting future trials and vaccine access?

Our immediate priority is to complete the comprehensive evaluation of the Phase 2 datasets from both studies and use those findings to determine the most appropriate path forward for clinical development. This includes assessing the optimal dose, formulationand vaccination schedule for children in LMIC´s as well as for adults at risk (e.g. travelersand defining the design of future studies. 

The FDA's Fast Track designation recognizes the significant unmet medical need that a Shigella vaccine could address and provides an important framework for interactions with regulators as the program advances. 

Partnerships will continue to play a critical role in the development of vaccines intended for global public health impact. The infant study was supported by the Gates Foundation, and collaboration with organizations focused on infectious diseases, global health, and equitable vaccine access can help support future clinical trials, facilitate implementation in endemic regions, and ultimately improve access for populations most affected by shigellosis. As we define the next stage of development, we will continue engaging with stakeholders who share the goal of reducing the burden of this disease

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close